The intervention will benefit ~60,000 women and children in selected areas of Delhi This initiative will prioritize nutrition outcomes by deepening partnership with the government to strengthen health and ICDS systems to promote evidence-based, sustainable, multi-sectoral actions for improved quality of health and nutrition
Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Private Limited), a global values-based, R&D-driven biopharmaceutical leader conducted dissemination of its public health initiatives in strengthening the health system for rare diseases (RD) in India. These initiatives aim to improve access to healthcare
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support Availability of a toll-free help line number 1800 103 4260 to provide coordination & counselling support for patients The initiative aims to drive HAE awareness through patient education, and timely
Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Pvt. Ltd.), a global values-based, R&D-driven biopharmaceutical leader, has been certified as a Great Place To Work® in India (March 2023 - March 2024). This certification has been awarded second time in a row to
Takeda Biopharmaceuticals India Private Limited Showcased Digital Innovations- MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting The Three-Day Meeting was Held in Goa, India, from April 17th to April 19th, 2023, and Side Event was Focused on: ‘Citizen-Centric Health Delivery Ecosystems
CINRYZE™ is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE. Among adult HAE patients, 51% miss at least one day of work (mean 3.3 days), 44% students miss at least one day of school
